Gadeta aims to develop a cancer treatment for all types of tumors
Gadeta is a clinical stage company developing innovative cell therapy treatments for difficult to target tumors.
We are using a number of proprietary T-cell engineering and manufacturing technologies. We are pioneering the development of αβ T-cells engineered to express defined γδ T-cell receptors that can specifically recognize cancer cells, eliminate them, and spare healthy cells. Gadeta has a pipeline of products in development for the treatment of haematologic malignancies and solid tumours.
Gadeta is a clinical stage biotechnology company developing a first-in-class cellular immunotherapy for the treatment of cancer, using a number of proprietary T-cell engineering and manufacturing technologies.
We are working on projects with the potential to change people's lives.
6 July 2021
Gadeta announced the dosing of the first patient with GDT-002. Read more here
2 June 2021
Gadeta launches new website